Chief Executive, Eli Lilly
We give money. We give medicines. We’re still going to do some of that, and that’s still important. But it’s not sufficient. We’re really, through our NCD program, applying the most precious commodity we have, which is our knowledge. We know a lot about the disease. We know a lot about treatment strategies. We probably don’t know as much as we could know about how to make diabetes diagnoses and treatment better in South Africa, or in Brazil, or in India or in Mexico, and that’s why we’re pursuing the NCD program.
I think that global enterprises are going to be self-motivated to get engaged with this. I see a lot of activity within certain American companies.